Management needs to find a big pharma to buy AMRN who could market Vascepa when it was estimated last year that would rake in billions of dollars in sales. I wonder where are those analysts that heralded that
Vascepa will be worth billions. Are they the same people who are shorting the stocks now and kicking it to
Considering debt, well over 100 million outstanding shares and potential 50-75 million annual sales , I would say probably....a buck a share....maybe 1.50...which will quickly head south as borrowing increases....they r currently running quartery deficits quickly depleting their cash reserves...stay away from this puppy....my 2 cents...
It is obviously worth less than $2 until Amarin announces a share buy back program or there is evidence of insider buying. If they have no confidence in Amarin at $2 why should any other investor. I would caution anyone to invest until the company indicates it is a great value at $2.
You do make a point about insiders buying. With all of insiders talk about not selling this until they get at least $30/share it seems they should put every penny they have in this stock but that being said BP did just buy a 'fish oil' company for $400 million which is above the current market cap for an inferior drug with less patents. I would think it would be great to invest more in this stock at these levels if I had extra powder but then again I also said that at $6/share
lol... share buy back. that's good stuff there. lets spend our cash on buying back shares so that operations aren't funded, sales dry up, we have no money to pay our debts and we assure ourselves a date in BK court.
Whatever you do, don't try running a business. Stay employed by someone who can make sure you don't make decisions.